Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (305)	10/19/2007 11:08:15 AM
From: Clarksterh	Read Replies (2) \| Respond to of 332

AtheroGenics, Inc. (NASDAQ: AGIX),... today announced the resignation of Rob Scott, M.D., Executive Vice President of Research & Development and Chief Medical Officer, to pursue other interests. So long to the public face of Atherogenics. This will probably have a big effect on how much and how reliable is the information coming out of Atherogenics. Will take time to recalibrate. Dr. Fleming is President and Chief Executive Officer of Kinexum LLC, a prominent life sciences consulting firm. The use of the present tense is odd. Is he not leaving his old job? Dr. Fleming served twelve years as FDA Supervisory Medical Officer for diabetes and other metabolic and endocrine disorders This is BFD. It significantly addresses one of the two wildcards - FDA acceptance of a diabetes drug with hints of liver tox. And it partially addresses the other wildcard - the trial being run in countries with a history of problems in randomized trials. Presumably, given his background in the FDA, Fleming has some insight into how diabetes trials fail. (One of the big problems in biotech is the bizarre inability of one company to learn from the mistakes of others - probably in part due to not really seeing the data from failed trials. The FDA probably provides a better opportunity than most to see a lot of failure.) But still an unknown. Need to research Dr. Fleming.